Vincerx Pharma Inc. (VINC)
0.15
-0.02 (-12.13%)
At close: Jan 15, 2025, 3:59 PM
0.16
5.99%
After-hours Jan 15, 2025, 04:54 PM EST
undefined% (undefined)
| Bid | 0.15 |
| Market Cap | 5.42M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -0.17 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.16 |
| Volume | 3,418,683 |
| Avg. Volume (20D) | 7,123,888 |
| Open | 0.16 |
| Previous Close | 0.17 |
| Day's Range | 0.14 - 0.17 |
| 52-Week Range | 0.14 - 9.37 |
| Beta | undefined |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat sol...
Industry Biotechnology
Sector Healthcare
IPO Date May 27, 2020
Employees 42
Stock Exchange NASDAQ
Ticker Symbol VINC
Website https://vincerx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VINC stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 1246.80% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-41.62%
Vincerx Pharma shares are trading lower. Leerink P...
Unlock content with
Pro Subscription
3 months ago ·
Source
-4.38%
Vincerx Pharma shares are trading higher after the company reported initial clinical data from its ongoing VIP939 Phase 1 dose-escalation study and provided pipeline and corporate updates.
